phrykt

PDS Biotechnology Corp (PDSB): who owns it and who trades it

As of Nov 12, 2026, no open-market insider purchases or sales of PDSB were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 12, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

No PDSB insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

PDSB short interest

Moderate short interest. 6.3% of PDSB shares are sold short: about 1 share in 16. Over the last 12 reports the number of shares short went up 91%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 3.52M PDSB shares were sold short, 6.3% of the shares outstanding, up 4.0% from the report before. At the average daily volume of 7.67M shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

6.29%May 15Oct 3012.8%

Days to cover

1.0May 15Oct 3011.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.52M6.29%+4%7.67M1.0
Oct 15, 20263.39M6.05%+22%16.41M1.0
Sep 30, 20262.77M4.95%-57%29.13M1.0
Sep 15, 20266.41M11.45%+173%97.84M1.0
Aug 31, 20262.35M4.20%+24%1.63M1.4
Aug 14, 20261.89M3.38%+3%4.29M1.0
Jul 31, 20261.83M3.28%+12%175,30310.5
Jul 15, 20261.63M2.92%+22%371,5414.4
Jun 30, 20261.34M2.40%-10%518,1462.6
Jun 15, 20261.49M2.68%-15%978,8171.5
May 29, 20261.76M3.15%-5%1.16M1.5
May 15, 20261.85M3.31%+8%998,8881.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

PDS Biotechnology company events

PDS Biotechnology filed 31 reports on Form 8-K in the last 12 months, 6 of them about an important change (leadership, listing). The latest was on Nov 10, 2026.

  1. Nov 10, 2026AnnouncementPDS Biotechnology Corporation issued a press release announcing that NantWorks has exercised its outstanding common stock warrants to purchase an aggregate of 17,699,115 shares of the Company's common stock (or pre-funded warrants in lieu thereof) at an exercise price of $0.22 per share. Filing
  2. Oct 21, 2026AnnouncementThe Company updated its corporate presentation deck. Filing
  3. Oct 20, 2026LeadershipEach of Kamil Ali-Jackson, Esq., Stephen Glover, Gregory Freitag, J.D., CPA, and Otis Brawley, M.D. notified the Board of Directors of PDS Biotechnology Corporation of his or her resignation as a member of the Board, and of each committee of the Board on which he or she served, effective immediately. Filing
  4. Oct 6, 2026AnnouncementPDS Biotechnology Corporation issued a press release announcing that the company will host a virtual key opinion leader (KOL) event featuring Jonathan M. Hernandez, M.D, an investigator with the Surgical Oncology Program at the National Cancer Institute’s Center for Cancer Research. Filing
  5. Sep 22, 2026AnnouncementPDS Biotechnology Corporation issued a press release announcing the publication of results from a Phase 2 trial evaluating PDS0101, its HPV16-targeted immunotherapy, in combination with pembrolizumab in the September 17, 2026, issue of JAMA Oncology, a peer reviewed journal of the American Medical… Filing
  6. Sep 21, 2026AnnouncementThe Company updated its corporate presentation deck. Filing
  7. Sep 14, 2026LeadershipPursuant to Section 5.14 of the previously disclosed Securities Purchase Agreement, dated September 7, 2026, by and among the Company and certain accredited investors (the Purchase Agreement was previously filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities… Filing
  8. Sep 8, 2026AgreementPDS Biotechnology Corporation, a Delaware corporation, entered into a Securities Purchase Agreement with certain accredited investors (each, a “ Purchaser ” and collectively, the “ Purchasers ”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to… Filing
  9. Sep 4, 2026AgreementPDS Biotechnology Corporation, a Delaware corporation, entered into a First Amendment to Promissory Note with YA II PN, Ltd., which amends that certain Promissory Note made by the Company in favor of the Holder, issued as of June 15, 2026, in the original principal amount of $6 million. Filing
  10. Aug 25, 2026LeadershipThe Company delivered a notice of termination without cause to Stephan Toutain and removed him from his position as the Company’s Chief Operating Officer. Filing
  11. Aug 19, 2026LeadershipLars Boesgaard submitted his resignation, effective as of September 12, 2026, as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of PDS Biotechnology Corporation in order to pursue other professional endeavors. Filing
  12. Aug 14, 2026VoteReported shareholder vote results. Filing
  13. Aug 13, 2026ResultsReleased financial results. Filing
  14. Aug 11, 2026AnnouncementShared information with investors. Filing
  15. Jul 31, 2026ListingPDS Biotechnology Corporation received a deficiency letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00… Filing
  16. Jun 15, 2026AgreementClosing of the Securities Purchase Agreement Transactions As previously disclosed in the Current Report on Form 8-K filed by PDS Biotechnology Corporation with the Securities and Exchange Commission on May 1, 2026, on April 30, 2026, the Company entered into a Securities Purchase Agreement with YA… Filing
  17. Jun 15, 2026AnnouncementThe board of directors of PDS Biotechnology Corporation has scheduled the Company’s 2026 Annual Meeting of Stockholders for August 10, 2026. Filing
  18. Jun 2, 2026AnnouncementAs previously disclosed, on February 25, 2026, PDS Biotechnology Corporation received a deficiency letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s… Filing
  19. May 13, 2026ResultsReleased financial results. Filing
  20. May 1, 2026AgreementPDS Biotechnology Corporation, a Delaware corporation, entered into a Securities Purchase Agreement with YA II PN, LTD., a Cayman Islands exempt limited company. Filing
  21. Apr 24, 2026AnnouncementThe Company updated its corporate presentation deck. Filing
  22. Apr 15, 2026AnnouncementPDS Biotechnology Corporation issued a press release announcing the publication of clinical and immunological biomarker data from Stage 1 of a Phase 2 trial evaluating its tumor-targeted IL-12 immunocytokine, PDS01ADC, in the March 10, 2026 issue of Journal of Clinical Oncology (JCO) Oncology… Filing
  23. Mar 30, 2026ResultsReleased financial results. Filing
  24. Mar 3, 2026ListingPDS Biotechnology Corporation received a deficiency letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00… Filing
  25. Feb 23, 2026AnnouncementThe Company updated its corporate presentation deck. Filing
  26. Feb 20, 2026AnnouncementPDS Biotechnology Corporation issued a press release announcing the adoption of a protocol amendment to its Phase 3 VERSATILE-003 clinical trial. Filing
  27. Jan 28, 2026AnnouncementPDS Biotechnology Corporation issued a press release announcing that results of a National Cancer Institute-led study of the Company’s investigational Interleukin-12 (IL-12) tumor targeted immunocytokine, PDS01ADC, were presented at the American Association of Cancer Research special conference on… Filing
  28. Jan 22, 2026AnnouncementPDS Biotechnology Corporation issued a press release announcing that U.S. Patent Office has issued a Notice of Allowance for the Company’s lead asset, PDS0101. Filing
  29. Jan 9, 2026AnnouncementPDS Biotechnology Corporation issued a press release announcing that the Company has submitted a protocol amendment to the U.S. Food and Drug Administration for its Phase 3 VERSATILE-003 clinical trial. Filing
  30. Dec 9, 2025AnnouncementPDS Biotechnology Corporation issued a press release announcing that the Japan Patent Office has issued Patent No. 7783866 for PDS0101 granting broad composition of matter and methods of use claims. Filing
  31. Dec 2, 2025AnnouncementPDS Biotechnology Corporation issued a press release announcing that its request for a Type C Meeting with the U.S. Food and Drug Administration has been accepted by the agency, and the meeting has been scheduled to occur this month. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

PDS Biotechnology financials

Famous investors that hold PDSB

1 of the 50 well-known investors we track reported holding PDSB in their latest 13F filing. The largest position is Jim Simons's, worth $466K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026621,346$466K0.0%+146%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named PDSB in the last 120 days.

FiledHolderFormStake
Nov 12, 2026Nant Capital, LLC13D/A19.9%
Nov 12, 2026Nant Capital, LLC13D/A19.9%

Questions about PDS Biotechnology Corp (PDSB) stock

Are PDSB insiders buying or selling?

No PDSB insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in PDSB?

As of Oct 30, 2026, 3.52M PDSB shares were sold short, 6.3% of the shares outstanding, up 4.0% from the report before. At the average daily volume of 7.67M shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Which famous investors hold PDSB?

1 of the 50 well-known investors we track reported PDSB in their latest 13F filing, including Jim Simons. The largest position is worth $466K. See all holders.

Executive pay

PDS Biotechnology's chief executive was paid a total of $828K for the year ended Dec 31, 2025, down 63% from $2.3M the year before. In the last 12 months, PDS Biotechnology's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$828KYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$630KThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$675KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.